Metraipolis › archive › dc_eccd7d2343be

The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic… — Europe PMC PMID:41583496

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41583496
DOI
10.3389/fimmu.2025.1708410
License (as archived)
solo-consultazione
Archived
2026-11-06T22:46:26.003Z
SHA-256 of the archived text
db77fad5c22fcf90a34c41eaef55acaf3ca63527d5e933dceb275cc981b4f62c
Stable URL of this page
https://metraipolis.com/documento/dc_eccd7d2343be

How to cite

The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic… — Europe PMC PMID:41583496 — Europe PMC (en), https://europepmc.org/article/MED/41583496 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_eccd7d2343be (Metraipolis archive dc_eccd7d2343be, sha256 db77fad5c22fcf90a34c41eaef55acaf3ca63527d5e933dceb275cc981b4f62c)
BibTeX
@misc{dceccd7d2343be,
  title = {The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic… — Europe PMC PMID:41583496},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41583496},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_eccd7d2343be; sha256 db77fad5c22fcf90a34c41eaef55acaf3ca63527d5e933dceb275cc981b4f62c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41583496. Agents can read the archived copy with the MCP tool read_document.